JP2008538749A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538749A5
JP2008538749A5 JP2008505929A JP2008505929A JP2008538749A5 JP 2008538749 A5 JP2008538749 A5 JP 2008538749A5 JP 2008505929 A JP2008505929 A JP 2008505929A JP 2008505929 A JP2008505929 A JP 2008505929A JP 2008538749 A5 JP2008538749 A5 JP 2008538749A5
Authority
JP
Japan
Prior art keywords
ethyl
propyl
phenoxy
ureido
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538749A (ja
Filing date
Publication date
Priority claimed from FR0503795A external-priority patent/FR2884516B1/fr
Application filed filed Critical
Publication of JP2008538749A publication Critical patent/JP2008538749A/ja
Publication of JP2008538749A5 publication Critical patent/JP2008538749A5/ja
Pending legal-status Critical Current

Links

JP2008505929A 2005-04-15 2006-04-14 Npy拮抗物質、調製および使用 Pending JP2008538749A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503795A FR2884516B1 (fr) 2005-04-15 2005-04-15 Antagonistes npy, preparation et utilisations
PCT/FR2006/000829 WO2006108965A2 (fr) 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations

Publications (2)

Publication Number Publication Date
JP2008538749A JP2008538749A (ja) 2008-11-06
JP2008538749A5 true JP2008538749A5 (enExample) 2009-04-09

Family

ID=35447654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505929A Pending JP2008538749A (ja) 2005-04-15 2006-04-14 Npy拮抗物質、調製および使用

Country Status (19)

Country Link
US (1) US20090233910A1 (enExample)
EP (1) EP1879887A2 (enExample)
JP (1) JP2008538749A (enExample)
KR (1) KR20080009112A (enExample)
CN (1) CN101198604A (enExample)
AP (1) AP2007004218A0 (enExample)
AU (1) AU2006234413A1 (enExample)
CA (1) CA2604773A1 (enExample)
CR (1) CR9514A (enExample)
EA (1) EA200800157A1 (enExample)
EC (1) ECSP077894A (enExample)
FR (1) FR2884516B1 (enExample)
IL (1) IL186601A0 (enExample)
MA (1) MA29444B1 (enExample)
MX (1) MX2007012847A (enExample)
NI (1) NI200700260A (enExample)
NO (1) NO20075322L (enExample)
TN (1) TNSN07376A1 (enExample)
WO (1) WO2006108965A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
EP1954287B2 (en) * 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
WO2007087443A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
CA2685029A1 (en) * 2007-04-26 2008-11-06 Avalon Pharmaceuticals Multi-ring compounds and uses thereof
EP2142529B1 (en) 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
JP2008303155A (ja) * 2007-06-06 2008-12-18 Ube Ind Ltd N−(ω−フルオロアルキル)環状アミン化合物の製法、並びに新規なN−(4−フルオロブチル)環状アミン化合物及びその製法
JP2009035537A (ja) * 2007-07-10 2009-02-19 Nippon Synthetic Chem Ind Co Ltd:The N−置換アニリン誘導体及び1−置換インドール誘導体の製造方法
BRPI0919816A2 (pt) * 2008-09-26 2019-09-24 Eisai R&D Man Co Ltd uso compostos benzoxazólicos no tratamento de malária
CN102272120B (zh) * 2008-11-07 2013-12-25 H.隆德贝克有限公司 生物活性酰胺
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Npyy5受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
WO2013010679A1 (en) 2011-07-15 2013-01-24 Novartis Ag Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
JP2015506371A (ja) * 2012-01-25 2015-03-02 デメルクス,インコーポレイテッド (1r,4r)7−オキソ−2−アザビシクロ[2.2.2]オクタ−5−エンおよびその誘導体
EP3145911B1 (en) 2014-05-21 2020-07-08 Solvay Specialty Polymers USA, L.L.C. Stabilizer compounds
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016187667A1 (en) * 2015-05-27 2016-12-01 Novogen Limited Functionalised and substituted indoles as anti-cancer agents
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP2017137259A (ja) * 2016-02-03 2017-08-10 株式会社Ihi 有機化合物の製造方法
WO2017141116A1 (en) 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
CN106543089A (zh) * 2016-11-04 2017-03-29 山东铂源药业有限公司 一种达沙替尼中间体的合成方法
CN107892656A (zh) * 2017-10-27 2018-04-10 苏州盖德精细材料有限公司 一种2,5‑二氨基苯乙醇的制备方法
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
CA3150700A1 (en) * 2019-09-17 2021-03-25 Renato T. Skerlj IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US20230295114A1 (en) * 2020-05-08 2023-09-21 Georgiamune Llc Akt3 modulators
KR102234530B1 (ko) * 2020-09-01 2021-03-31 대한민국 신규 톨트라주릴 유도체 및 이를 포함하는 쿠도아충 예방·치료를 위한 약학 조성물
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途
CN118206542B (zh) * 2023-03-22 2025-06-27 沈阳药科大学 一种化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用
CN117003672B (zh) * 2023-08-09 2024-05-28 湖南正量工程技术有限公司 一种boc-4,4’-二硝基二苯胺的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06248153A (ja) * 1993-03-01 1994-09-06 Shin Etsu Chem Co Ltd 難燃樹脂組成物
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
ATE232200T1 (de) * 1998-06-08 2003-02-15 Schering Corp Neuropeptid y5-rezeptorantagonisten
JP2000287697A (ja) * 1999-02-05 2000-10-17 Shionogi & Co Ltd Npy受容体親和性を有するラクトン誘導体
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
MXPA03002263A (es) * 2000-09-14 2003-06-24 Schering Corp Antagonistas de receptor de neuropeptido y y5 de urea sustituidos.
AU2002355286B2 (en) * 2001-07-26 2005-10-13 Schering Corporation Substituted urea neuropeptide Y Y5 receptor antagonists
BR0308108A (pt) * 2002-02-28 2004-12-07 Hoffmann La Roche Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
DE50311923D1 (de) * 2002-07-11 2009-10-29 Sanofi Aventis Deutschland Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension

Similar Documents

Publication Publication Date Title
RU2412192C2 (ru) Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2
EP2239012A2 (en) Pharmaceutical use of substituted amides
JP2008538749A (ja) Npy拮抗物質、調製および使用
US20060111366A1 (en) Pharmaceutical use of substituted amides
US20090163482A1 (en) Tetralines antagonists of the h-3 receptor
US20070197530A1 (en) Amido compounds and their use as pharmaceuticals
JP2006522744A (ja) グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
JP2006522746A5 (enExample)
JP2006522750A5 (enExample)
US20060122197A1 (en) Amido compounds and their use as pharmaceuticals
US20090137574A1 (en) Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders
US20110251172A1 (en) Purine derivatives for treatment of alzheimer's disease
WO2004089416A2 (en) Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
JP2006522744A5 (enExample)
JP2008520695A (ja) 5−ht2aセロトニン受容体媒介障害の処置に有用な5−ht2aセロトニン受容体のモジュレーターとしての3−フェニル−ピラゾール誘導体の使用
BRPI0715513A2 (pt) inibidores de epàxido hidrolase solével
KR20020010916A (ko) Nos 억제제로서의 신규한 약학 혼합물
JP2007531755A5 (enExample)
US20040229911A1 (en) New pharmaceutical combinations for NOS inhibitors
CN101405265A (zh) 酰氨基化合物及其作为药物的应用
JP7862858B2 (ja) Mps1を処置するための併用療法
ZA200305318B (en) Therapeutic chroman compounds.
EP1862181A2 (en) Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP1854487A2 (en) Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
MX2008009668A (en) Amido compounds and their use as pharmaceuticals